PROTAC ER Degrader-2
PROTAC ER Degrader-2 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab) [1].
Product Specifications
UNSPSC
12352005
Target
Estrogen Receptor/ERR; PROTAC-Linker Conjugates for PAC
Type
Reference compound
Related Pathways
Antibody-drug Conjugate/ADC Related; PROTAC; Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/protac-er-degrader-2.html
Solubility
10 mM in DMSO
Smiles
Molecular Formula
C89H104N12O15
Molecular Weight
1581.85
References & Citations
[1]Thomas Pillow, et al. Protac antibody conjugates and methods of use. WO2017201449A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Lentiviral mouse Elf1 shRNA (UAS) - Lentiviral mouse Elf1 shRNA (UAS, RFP) (25)
